Compound 60 has an exceptionally high affinity to MDM2 (Ki < one nM), strong cellular action, and a very good oral pharmacokinetic profile. Compound sixty is capable of attaining entire and very long-lasting tumor regression in vivo and it is at the moment in phase I clinical trials for cancer https://augustineb085tye9.wikicommunications.com/user